Gina Columbus reports on an FDA breakthrough therapy designation in lung cancer, encouraging results with CAR T-Cell therapy in non-Hodgkin lymphoma, disappointing results in myeloma, a promising combination in follicular lymphoma, and highlights from the 2016 NCCN Hematologic Malignancies Congress.

свернуть